Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn Acquires 85,000 Shares of Stock

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn bought 85,000 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was purchased at an average price of $0.97 per share, for a total transaction of $82,450.00. Following the completion of the acquisition, the director now directly owns 299,286 shares in the company, valued at $290,307.42. The trade was a 39.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Generation Bio Trading Up 6.6 %

Shares of GBIO opened at $0.95 on Friday. Generation Bio Co. has a twelve month low of $0.75 and a twelve month high of $4.65. The stock’s 50 day moving average is $1.30 and its two-hundred day moving average is $2.11. The firm has a market capitalization of $63.20 million, a PE ratio of -0.43 and a beta of 2.72.

Hedge Funds Weigh In On Generation Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in Generation Bio by 31.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock valued at $527,000 after buying an additional 44,378 shares in the last quarter. Rhumbline Advisers increased its position in Generation Bio by 7.4% during the 2nd quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock worth $222,000 after purchasing an additional 5,430 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Generation Bio by 199.3% in the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after acquiring an additional 21,167 shares during the period. Cubist Systematic Strategies LLC boosted its position in shares of Generation Bio by 91.0% in the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after buying an additional 9,075 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Generation Bio by 8.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock valued at $464,000 after buying an additional 13,104 shares during the period. 95.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Needham & Company LLC lowered their price objective on shares of Generation Bio from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research note on Thursday, November 7th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.